Lung metastases are most common in clear cell renal cell carcinoma, whereas lymph node metastases and liver metastases occur most frequently in papillary and chromophobe RCC, respectively, investigators reported.
Previous findings from the TIVO-3 trial showed that tivozanib offered superior progression-free survival compared with sorafenib in patients with refractory metastatic renal cell carcinoma, but the latest analysis found no significant difference in overall survival.
Updated findings from KEYNOTE-426 showed that frontline pembrolizumab-axitinib continued to be associated with improved PFS and OS compared with sunitinib in advanced RCC.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
